Editor’s Choice: Selected Research Highlights from Autoimmunity Journals

Single-cell transcriptomic analysis uncovers heterogeneity in the labial gland microenvironment of primary Sjögren's syndrome 新しいタブ／ウィンドウで開く This research employs single-cell transcriptomics to reveal the complex cellular landscape within the labial glands of patients with primary Sjögren's syndrome. The findings indicate significant heterogeneity, which may inform targeted therapeutic approaches.

Cellular therapies in rheumatic and musculoskeletal diseases 新しいタブ／ウィンドウで開く This article reviews the current landscape of cellular therapies in treating rheumatic and musculoskeletal diseases, discussing recent advances, challenges, and future directions for these innovative treatments.

Urinary soluble CD163 is useful as “liquid biopsy” marker in lupus nephritis at both diagnosis and follow-up to predict impending flares 新しいタブ／ウィンドウで開く The study investigates urinary soluble CD163 as a potential liquid biopsy marker for lupus nephritis. The results demonstrate its utility in diagnosing and monitoring disease progression, offering insights into predicting flares in affected patients.

Advances in chimeric antigen receptor T cell therapy for autoimmune and autoinflammatory diseases and their complications 新しいタブ／ウィンドウで開く This paper highlights recent advances in chimeric antigen receptor (CAR) T cell therapy, exploring its applications in treating autoimmune and autoinflammatory diseases. The authors discuss both the potential benefits and complexities of this therapy.

Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma 新しいタブ／ウィンドウで開く This research reports on the survival outcomes of patients with inflammatory arthritis who were treated with immune checkpoint inhibitors for melanoma. The findings suggest that these patients may experience poorer survival rates, raising important clinical considerations.

Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agents in autoimmune diseases 新しいタブ／ウィンドウで開く The article evaluates the potential of glucagon-like peptide-1 receptor agonists as disease-modifying agents in various autoimmune conditions. The authors discuss the mechanisms of action and clinical implications of these therapies.

Global, regional, and national burden of inflammatory bowel disease and its associated anemia, 1990 to 2019 and predictions to 2050: An analysis of the global burden of disease study 2019 新しいタブ／ウィンドウで開く This comprehensive analysis assesses the global and regional burden of inflammatory bowel disease (IBD) and associated anemia from 1990 to 2019, with projections to 2050. The findings highlight the growing public health challenge posed by IBD.

Is fibromyalgia an autoimmune disorder 新しいタブ／ウィンドウで開く? This thought-provoking article explores the controversial question of whether fibromyalgia should be classified as an autoimmune disorder. The authors review existing literature and propose a framework for understanding the condition in relation to autoimmune mechanisms.

Subclinical giant cell arteritis in polymyalgia rheumatica: Concurrent conditions or a common spectrum of inflammatory diseases? 新しいタブ／ウィンドウで開く The study examines the relationship between subclinical giant cell arteritis and polymyalgia rheumatica, questioning whether these conditions represent concurrent diseases or part of a broader spectrum of inflammatory disorders.